| Name | Succinobucol |
| Description | Succinobucol (Probucol monosuccinate) is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease. |
| Cell Research | In the metastatic 4T1 breast cancer cells, Succinobucol, SCB and the PCD polymer (equivalent concentration to SCB) are respectively added to each well with SCB concentrations ranging from 4 ng/mL to 40 μg/mL. |
| Animal Research | Mice, injected 4T1-luc cells, are treated with Succinobucol (40 mg/kg) by tail injection every three days. |
| In vitro | In rabbit whole blood, Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO. |
| In vivo | In lung metastatic breast cancer mice, Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules. In rats, Succinobucol (50, 100, and 150 mg/kg, i.v.) has no significant effect on either heart rate or MAP. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (72.94 mM)
|
| Keywords | Inhibitor | inhibit | Probucol Monosuccinate | AGI1067 | Reactive Oxygen Species | Succinobucol | Probucol | AGI 1067 |
| Inhibitors Related | Sodium Thiocyanate | L-Ascorbic acid | α-Vitamin E | Propyl gallate | L-Tartaric acid | Glucosamine | Neohesperidin | D-(+)-Glucono-1,5-lactone | L-Cystine | 3-Amino-1,2,4-triazole | Lycopene | Naringenin |
| Related Compound Libraries | Ferroptosis Compound Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Fibrosis Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
